U.S. to Dominate the Immuno-Oncology Drugs Market, Owing to High Prevalence of Cancer
Immuno oncology is a type of cancer therapy designed to strengthen the body’s immune system to fight the cancer. These immunotherapies such as immune checkpoint inhibitor or cell transfer therapyimprove immune response of the patient against cancerous cells. Immunotherapies either act against immune checkpoint produced by cancer cells that reduces the intensity of immune responses towards them or stimulate the activities of specific components of the immune system. Immune checkpoint inhibitors is the most widely used therapy.
Increasing prevalence of cancer to fuel growth of immuno-oncology drugs market
According to World Health Organization (WHO), cancer is one of the major non-communicable diseases and the second-leading cause of death worldwide. According to International Agency for Research on Cancer (IARC) in 2012, there were around 14.1 million new cases, 8.8 million deaths, and 32.6 million people living with cancer worldwide. Immuno-oncology therapy is effective for treatment of cancers such as melanoma, bladder cancer, head and neck cancer, leukemia, lung, multiple myeloma, lymphoma, and renal cancer. Furthermore, immuno-oncology has less side effect than chemotherapy, radiation therapy, and surgery. There are many immuno-oncology drugs in the pipeline such as CAR-T cell therapy offered by Juno Therapeutics, Inc and Kite Pharma. Immuno-oncology drugs has proven clinical profile and increasing approvals to include more indicationfor existing drugs such as nivolumab is in turn expected to boost growth of the immuno-oncology drugs market.
However, high costs associated with therapy is restraining growth of the immuno-oncology drugs market. Immuno oncology drugs prescribed with chemotherapy increases the cancer treatment cost. According to Immuno-Oncology Summit Europe 2017, combination of immunotherapy with chemotherapy and targeted therapy improves survival rate of cancer patient. In 2017, Merck & Company received approval for immune checkpoint inhibitor brand Keytruda (pembrolizumab) for its use in combination with other anti-cancer drugs such as pemetrexed and carboplatin in non-squamous non-small cell lung cancer.
Immuno-oncology drugs market taxonomy:
On the basis of immunotherapy type:
- Immune checkpoint inhibitors
- Monoclonal antibody based drugs
- Adoptive cell transfer therapy (CAR-T Cell therapy ,TCR Therapy, TIL Therapy)
- Anti-body drug conjugates
- Cytokine based immunotherapy
- Vaccines
On the basis of cancer type:
- Lung cancer
- Melanoma
- Bladder cancer
- Leukemia
- Lymphoma
- Multiple Myeloma
- Head and neck cancer
- Others
On the basis of distribution channel:
- Hospital Pharmacy
- Retail Pharmacy
To know the latest trends and insights prevalent in the market, click the link below:
https://www.
U.S. to dominate the immuno-oncology drugs market, owing to high prevalence of cancer
The U.S. has a robust healthcare infrastructure and is characterized by high availability of novel anti-cancer therapy options. According to a report published in American Cancer Society’s Cancer Journal for Clinicians, around 1,735,350 new cancer cases are estimated to be diagnosed in 2018 in U.S., including around 87,290 cases of melanoma, for which drugs such as ipilimumab (Brand-Yeroy) and pembrolimumab (Brand-Keytruda) have been approved. Furthermore, expansion of indications for already approved drug would open up new opportunities for immuno-oncology market. Currently, atezolizumab (Brand-Tecentriq) is indicated for type of cancers such as melanoma, bladder cancer, head and neck cancer FDA granted accelerated approval to Tecentriq for the treatment of people with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy
- Durvalumab (Imfinzi) was approved in 2017 as immune checkpoint inhibitor, which blocks interaction of PD-L1 with PD-1 and CD80.
- In December 2017, nivolumab (Opdivo) received approval for adjuvant treatment of melanoma.
- In August 2017, Novartis received approval for CAR-T therapy named Kymriah for children and young adult with B- cell lymphoblastic lymphoma.
- Gilead Life Science completed the acquisition of Kite pharma Ltd. in October 2017, for around US$ 1.3 billion. Gilead’s CAR-T therapy Yescarta received FDA approval in October 2017 to treat non-Hodgkin lymphoma.
- Celgene Corporation, in January 2018, announced acquisition of Juno Therapeutics, Inc. for US$ 9 billion. Through this acquisition, Celgene Corporation would gain access to novel CAR-T therapy, which is in pipeline of Juno Therapeutics.
- Amgen received FDA approval in 2017, for Imlygic, which is an oncolytic virus to treat melanoma.
- In March 2017, FDA approved the avelumab (Bavencio) in metastatic Merkel cell carcinoma which is rare disease, EMD serono and Pfizer Inc. jointly developed it.
Key players operating in the immuno-oncology drugs market include Amgen Inc., AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co, F. Hoffmann-La Roche AG, Johnson & Johnson,, Novartis International AG, Abbvie, Inc., Pfizer Inc., EMD Serono, Inc. and Gilead Lifescinces Inc.
